Last reviewed · How we verify
Carvedilol 50 mg
At a glance
| Generic name | Carvedilol 50 mg |
|---|---|
| Also known as | Coreg |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Dizziness
- Nasopharyngitis
- Dyspepsia
- Chest pain
- Chest discomfort
- Pollakiuria
- Ischaemia
- Cerebral infarction
- Migraine
- Abdominal discomfort
- Constipation
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) (PHASE2)
- Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices (PHASE4)
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (PHASE3)
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis (PHASE4)
- Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (PHASE4)
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices (NA)
- Exercise as an Immune Adjuvant for Allogeneic Cell Therapies (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |